Carcinoma  >>  linsitinib (ASP7487)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
linsitinib (ASP7487) / Sling Therap
NCT01101906 / 2010-018739-17: A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

Terminated
2
23
US, Europe, RoW
OSI-906, Placebo
Astellas Pharma Inc
Advanced Hepatocellular Carcinoma (HCC)
11/11
12/11
NCT01533246: Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Completed
2
17
US
linsitinib, OSI-906, laboratory biomarker analysis
National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
11/12
11/12
NCT01221077: Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Completed
2
88
Canada, US, RoW
OSI-906, Erlotinib, OSI-774, Tarceva, Placebo
Astellas Pharma Inc
NSCLC, Non Small Cell Lung Cancer
03/13
09/14
NCT01186861 / 2010-020916-12: Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Completed
2
205
Canada, US, Europe, RoW
OSI-906, erlotinib, OSI-774, Tarceva, placebo
Astellas Pharma Inc
Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
07/13
03/15
NCT01533181: Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

Completed
2
44
US, RoW
Laboratory Biomarker Analysis, Linsitinib, IGF-1R inhibitor OSI-906, OSI-906, OSI-906AA, Pharmacological Study, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI)
Recurrent Small Cell Lung Carcinoma
11/14
11/14
NCT01427205: Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Withdrawn
2
0
US
Cetuximab, C225, Erbitux, IMC-C225, OSI-906, Placebo, sugar pill
M.D. Anderson Cancer Center, OSI Pharmaceuticals
Head and Neck Cancer
06/16
 
NCT01600807: OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Withdrawn
1/2
0
US
Gemcitabine, Erlotinib, OSI-906, Gemzaar, Tarceva, Gemcitabine, Erlotinib
Dana-Farber Cancer Institute
Pancreatic Cancer, Metastatic
 
 
NCT01465815: Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Withdrawn
1/2
0
US
erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, linsitinib, OSI-906, placebo, PLCB, radiation therapy, irradiation, radiotherapy, therapy, radiation, therapeutic conventional surgery, laboratory biomarker analysis
OHSU Knight Cancer Institute, National Cancer Institute (NCI)
Recurrent Skin Cancer, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Squamous Cell Carcinoma of the Skin, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
09/13
09/13

Download Options